Program

Program

Thursday February 10th

09.00-09.10 Welcome address
Maria F Gomez, coordinator – EXODIAB; Lund University Diabetes Centre

Session 1 How to classify diabetes in precision medicine, chair: Anita Öst

09.10-09.30 John Nolan, Trinity College, Dublin, Ireland
“How to classify Diabetes: towards Precision Medicine”

09.30-09.50 Simon J Griffin, University of Cambridge, UK
Spurious precision: Pitfalls and perils of personalised medicine”

09.50-10.10 Patricia Zaharia, German Diabetes Centre, Düsseldorf, DE
“Role of novel diabetes subphenotypes for preventive and therapeutic strategies”

10.10-10.30 John Nolan, Simon J Griffin, Patricia Zaharia
“Subclassification of diabetes – Questions and answers”

10.30-11.10 Coffee, exhibitions

Session 2: Cardiovascular complications in diabetes, chair: Isabel Goncalves

11.10-11.40 John Pernow, Karolinska institute, SE
“Diabetes and cardiovascular comlications: novel mediators and therapeutic targets”

11.40-12.10 Andreas Edsfeldt, Lund University, SE
“Underlying vascular changes in type 2 diabetes”

12.10-13.10 Lunch and exhibitions

Session 3: Hormone signalling and resistance, chair: Olga Göransson

13.10-13.40 Maria Pereira, Uppsala University, SE
“Glucocorticoids and adipocyte metabolism: old hormones, new targets”

13.40-14.10 Anna Benrick, Gothenburg University, SE
“Developmental programming by maternal adiponectin”

14.10-14.30 Coffee, exhibitions

Session 4: Younger research session/abstract session, chair: Younger researcher committee: Rashmi Prasad, Elin Chorell, Linda Engström-Ruud, Rongrong Fan

14.30-17.00 Younger researcher session, abstract session

Omar Hmeadi, Uppsala university, “Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes”

Teresa Pereira, Karolinska Institute, “Treatment with the HIF-1a inhibitor PX-478 preserves pancreatic b cell function in diabetes”

Ceren Incedal, Uppsala University, “The primary cilium is an automonous Ca 2++ organelle that detects paracrine GABA signalling in pancreatic beta-cells”

Mingyu Yang, Uppsala University, “Genetically encoded sensors and organic dyes report Ca2+ differently in b‑cells”

Ben King, Lund University, “Intracellular cytosolic C3 protects pancreatic b-cells from IL-1beta-driven cytotoxicity”

Lucie Colineau, Lund University, “Investigating the role of C3 in type 2 diabetes onset using mouse models”

Santiago Echeverry, Uppsala University, “Munc13 regulates in insulin exocytosis by two distinct Ca2+-dependent mechanisms”

Alexandros Karagiannopoulos, Lund University, “Human pancreatic islet miRNA-mRNA networks of altered miRNAs due to glycaemic status”

Cecilia Skoug, Lund University, “Alterations in the sphingosine 1-phosphate receptors density in membranes and nerve-terminals from the cerebral cortex of type 2 diabetes models”

Gabriella de Paula, Lund University, “Fat-induced energy metabolism alterations in BV-2 microglia cells”

João Vieira, Lund University, “Nuclear magnetic resonance (NMR) spectroscopy characterization of metabolic alterations: Interaction between obesity-induced Type 2 Diabetes and stroke”

Rui Simoes, Lund University, “Obesogenic diet-induced hypothalamic inflammation is a gender specific, reversible process”

Charlene Perian, Gothenburg University, “Collagen I fragments promote inflammation, fibrosis and angiogenesis in the subcutaneous adipose tissue”

Isabella Broderick, Gothenburg University, “Sex difference in subcutaneous adipose tissue collagen organization and macrophage function”

Marcos Bauza Thorbrügge, Gothenburg University, “Adipocyte-specific ablation of the Ca2+ pump SERCA2 impairs whole-body metabolic function and reveals the diverse metabolic flexibility of white and brown adipose tissue”

Milica Vujicic, Gothenburg University, “Resident M2-like macrophages play critical role in healthy subcutaneous adipose tissue expansion via CD206-mediated collagen endocytosis”

(Narmadha Subramanian, Karolinska Institute, “Role of adipose tissue inflammation in cardiovascular disease in non-obese individuals”) Will not participate

Belen Avila, Argentina Diabetes Federation, “Exploring psychological impact of the COVID-19 pandemic on people with diabetes in Argentina during 2020”

Julia Sanchez-Ceinos, Karolinska Institute, “Inhibition of EZH2 methyltransferase blunts hyperglycaemia-induced oxidative stress and inflammation in human endothelium”

Michael Miskelly, Lund University, “RNA sequencing unravels novel L-cell constituents and mechanisms of GLP-1 secretion in gastric bypass-operated intestine”

Anja Schmidt-Christensen, Lund University, “Synchrotron X-ray micro-CT imaging for resolving complex 3D structural changes in the kidney: a missing piece of information needed to understand and potentially predict DKD progression and response to treatment”

Phathu Muthelo, Uppsala University, “Sensitive autoimmunity detection through Proximity Assays”

Tilda Herrgårdh, Linköping University, “Digital twin for weight-driven insulin resistance in humans: diet and drug-interventions”

Session 5: Keynote Lecture I, Chair: Jorge Ruas

17.00-18.00 Bruce Spiegelman, Harvard University, Boston, US

“Adipose Cells and Diabetes: Biochemical Pathways and Therapeutic Opportunities”

Friday February 11th

Session 6: Diabetic kidney disease: novel concepts and therapies, chair: Julia Otten

09.00-09.30 Simon Satchell, University of Bristol, UK
“Endothelial glycocalyx in the pathogenesis of microvascular complications of diabetes”

09.30-10.00 Hiddo Lambers Heerspink, University medical Center Groningen, NL
“SGLT2 inhibitors and kidney protection: What have we learned and how does the future look like?”

10.00-10.30 Coffee, exhibitions

Session 7: Non-pharmacological interventions in diabetes, chair: Tommy Olsson

10.30-11.00 Mike Lean, University of Glasgow, UK
“Remission of type 2 diabetes with the DiRECT diet programme: new insights into the disease-process and its management”

11.00-11.30 Julia Otten, Umeå University, SE
“Type 2 diabetes remission using diet replacement and eHealth”

11.30-12.15 Lunch, exhibitions

Session 8: Type 1 diabetes – Innate and adaptive immunity, chair: Ulf Ahlgren

12.15-12.45 Malin Flodström-Tullberg, Karolinska Institute, SE
“A viral trigger for type 1 diabetes”

12.45-13.15 Anna Blom, Lund University, SE
“Novel intracellular splice variants of complement inhibitor CD59 control insulin secretion”

Session 9: Human islets in diabetes research, chair: Hindrik Mulder

13.15-13.45 Patrik Rorsman, Sahlgrenska Institute SE and Oxford University, UK
“Metabolic regulation of glucagon secretion: from the clinic to the test tube and back”

13.45-14.15 Maike Sander, University of San Diego, US
“Insights into islet cell gene regulation from single-cell chromatin analyses”

14.15-14.45 Al Powers, Vanderbilt University, US
“Human islets as a research tool: proper and reproducible procedures in research”

14.45-15.00 Coffee

Session 10: Keynote Lecture 2, Chair: Anita Öst

15.00-16.00 Jens Juul Holst, Copenhagen University, DK
“Glucagon: old player, novel role”

16.00-16.10
Competition result

Quiz result

16.10-16.15
Closing remarks – Organizing committee